MX2009013575A - Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa. - Google Patents
Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa.Info
- Publication number
- MX2009013575A MX2009013575A MX2009013575A MX2009013575A MX2009013575A MX 2009013575 A MX2009013575 A MX 2009013575A MX 2009013575 A MX2009013575 A MX 2009013575A MX 2009013575 A MX2009013575 A MX 2009013575A MX 2009013575 A MX2009013575 A MX 2009013575A
- Authority
- MX
- Mexico
- Prior art keywords
- fti
- sensitivity
- hh2ax
- biomarker
- histone h2ax
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere por ejemplo, a métodos para predecir sensibilidad celular a inhibidores de farnesil proteína transferasa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94335307P | 2007-06-12 | 2007-06-12 | |
PCT/US2008/007294 WO2008156613A1 (en) | 2007-06-12 | 2008-06-11 | Histone h2ax (hh2ax) biomarker for fti sensitivity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009013575A true MX2009013575A (es) | 2010-07-02 |
Family
ID=39764863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009013575A MX2009013575A (es) | 2007-06-12 | 2008-06-11 | Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa. |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110009387A1 (es) |
EP (1) | EP2171447A1 (es) |
JP (1) | JP2010529479A (es) |
CA (1) | CA2690556A1 (es) |
MX (1) | MX2009013575A (es) |
WO (1) | WO2008156613A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3007411B1 (fr) * | 2013-06-21 | 2015-07-03 | Agronomique Inst Nat Rech | Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
DK3122426T3 (da) | 2014-03-28 | 2023-04-03 | Univ Duke | Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer |
WO2016126616A1 (en) | 2015-02-02 | 2016-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax |
EP4039253A1 (en) | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Methods of treating cancer |
RS62660B1 (sr) * | 2016-09-27 | 2021-12-31 | Radius Pharmaceuticals Inc | Rad1901 za upotrebu u lečenju karcinoma jajnika |
EP3565542B1 (en) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
AU2019297421A1 (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD 1901-2HCL |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1478773B1 (en) * | 2001-10-30 | 2007-09-19 | Ortho-Clinical Diagnostics, Inc. | Methods for assessing acute myeloid leukemia |
EP1502962A3 (en) * | 2003-07-01 | 2006-01-11 | Veridex, LLC | Methods for assessing and treating cancer |
WO2006042035A2 (en) * | 2004-10-07 | 2006-04-20 | Pharmacyclics, Inc. | Method of monitoring anti-tumor activity of an hdac inhibitor |
-
2008
- 2008-06-11 WO PCT/US2008/007294 patent/WO2008156613A1/en active Application Filing
- 2008-06-11 US US12/601,643 patent/US20110009387A1/en not_active Abandoned
- 2008-06-11 CA CA2690556A patent/CA2690556A1/en not_active Abandoned
- 2008-06-11 MX MX2009013575A patent/MX2009013575A/es unknown
- 2008-06-11 EP EP08768350A patent/EP2171447A1/en not_active Withdrawn
- 2008-06-11 JP JP2010512176A patent/JP2010529479A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2008156613A1 (en) | 2008-12-24 |
JP2010529479A (ja) | 2010-08-26 |
EP2171447A1 (en) | 2010-04-07 |
CA2690556A1 (en) | 2008-12-24 |
US20110009387A1 (en) | 2011-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009013575A (es) | Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa. | |
WO2011163423A3 (en) | Methods and compositions for cell permeable stat3 inhibitor | |
EA200802285A1 (ru) | Бивалентные миметики smac и их применения | |
EA201270553A1 (ru) | Ингибиторы тирозинкиназы брутона | |
MX2009011069A (es) | Mimeticos de smac diazo biciclicos y usos de los mismos. | |
CY1118012T1 (el) | Συνθεσεις αναστολεων κινασης και η χρηση αυτων για την αγωγη καρκινου και αλλων νοσηματων σχετικων προς τις κινασες | |
WO2009005809A3 (en) | Compositions and methods for treating and diagnosing cancer | |
BR112012011528A2 (pt) | métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto | |
EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
MX363201B (es) | Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico. | |
WO2012096545A3 (ko) | 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도 | |
MX2012012615A (es) | Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs). | |
EA201201036A1 (ru) | Целевые геномные изменения | |
WO2012178208A3 (en) | Selective inhibitors of histone deacetylase isoform 6 and methods thereof | |
EA201391329A1 (ru) | Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) | |
EA200702361A1 (ru) | АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ | |
CL2012003104A1 (es) | Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende. | |
WO2006055880A3 (en) | Diagnostic pkm2 methods and compositions | |
Pouliquen et al. | Biomarkers of tumor invasiveness in proteomics | |
EP2516624A4 (en) | CELL LINE 3M | |
EP1899463A4 (en) | BIOMARKERS FOR EVALUATING THE PROBABILITY THAT A TUMOR IS SENSITIVE TO A MTOR INHIBITOR | |
WO2009126947A3 (en) | Heteroaryl-substituted bicyclic smac mimetics and the uses thereof | |
WO2007118242A3 (en) | Identification of a constitutively resistant cancer stem cell | |
MY146366A (en) | Monoclonal antibodies, hybridoma cell lines, methods and kits for detecting phytase | |
AU2012236134A8 (en) | Biomarkers for predicting sensitivity to cancer treatments |